公开(公告)号：GEP20186893B

公开(公告)日：2018-09-10

申请号：GEAP2015014266

申请日：2015-02-13

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： TAKEDA PHARMACEUTICAL COMPANY LIMITED

IPC: A61P25/00 ,  A61K31/497 ,  A61K31/5377 ,  C07D241/26 ,  C07D241/28 ,  C07D401/04

Abstract: Compound of formula I, I pharmaceutical compositions on basis thereof and their usage at the treatment of conditions related to GPR6. Table: 1

公开(公告)号：IL220509A

公开(公告)日：2016-07-31

申请号：IL22050912

申请日：2012-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Abstract: Disclosed are compounds of Formula 1,and pharmaceutically acceptable salts thereof, wherein G, L 1 , L 2 , R 1 , R 2 , R 3 , and R 4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

公开(公告)号：AU2006232993B2

公开(公告)日：2012-01-19

申请号：AU2006232993

申请日：2006-03-13

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  WATSON PHARMACEUTICALS INC

Inventor： CARDINAL JACK R ,  OKOCHI KAZUHIRO ,  LODIN UNCHALEE NORTHEAST TH PLACE NORTH MIAMI BEAR ,  NANGIA AVINASH

IPC: A61K9/00 ,  A61K9/20 ,  A61K9/22 ,  A61K9/24 ,  A61K9/26 ,  A61K9/28 ,  A61K31/155 ,  A61K31/425 ,  A61K31/426 ,  A61K45/06

Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

公开(公告)号：FI2300013T4

公开(公告)日：2025-02-04

申请号：FI09751617

申请日：2009-05-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： WANG YIHAN ,  HUANG WEI-SHENG ,  LIU SHUANGYING ,  SHAKESPEARE WILLIAM ,  THOMAS R ,  QI JIWEI ,  LI FENG ,  ZHU XIAOTIAN ,  KOHLMANN ANNA ,  DALGARNO DAVID ,  ROMERO JAN ,  ZOU DONG

IPC: A61K31/505 ,  A61K31/513

Abstract: The invention features compounds of the general formula (VIa) in which the variable groups are as defined herein, and to their preparation and use.

公开(公告)号：GEP20196942B

公开(公告)日：2019-02-11

申请号：GEAP2015014401

申请日：2015-06-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： TAKEDA PHARMACEUTICAL COMPANY LIMITED

IPC: C07D217/14 ,  A61K31/4375 ,  A61K31/472 ,  A61K31/4741 ,  A61P11/06 ,  A61P17/06 ,  A61P19/02 ,  A61P43/00 ,  C07D471/04 ,  C07D491/14

Abstract: An invention relates to heterocyclic compounds of RORγt inhibitive activity, of formula (I), or salt thereof; and their usage at psoriasis, crown desease, multiple sclerosis, etc. treatment, as well.

公开(公告)号：MA38391B1

公开(公告)日：2018-09-28

申请号：MA38391

申请日：2014-03-10

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： LAWSON JOHN DAVID ,  SABAT MARK ,  SCORAH NICHOLAS ,  SMITH CHRISTOPHER ,  VU PHONG H ,  WANG HAIXIA

IPC: A61K31/4725 ,  A61P35/00 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14

Abstract: L'invention concerne des composés de formule 1 ou des sels pharmaceutiquement acceptables de ceux-ci, dans la formule, r1, r2, r3, et r4 sont tels que définis dans la description. Cette invention concerne également des matières et des procédés permettant de préparer les composés de formule 1, des compositions pharmaceutiques contenant ces composés, ainsi que leur utilisation pour traiter des réactions d'hypersensibilité de type i, des maladies auto-immunes, des troubles inflammatoires, le cancer, des troubles proliférants bénins, et d'autres états associés à la tyrosine kinase de bruton (btk).

公开(公告)号：GB201616839D0

公开(公告)日：2016-11-16

申请号：GB201616839

申请日：2016-10-04

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

公开(公告)号：WO2023073645A1

公开(公告)日：2023-05-04

申请号：PCT/IB2022/060413

申请日：2022-10-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  MORPHOSYS AG

Inventor： HUSZAR, Dennis ,  PROSCURSHIM, Igor

IPC: A61P35/00 ,  A61K31/34 ,  A61K39/395 ,  A61P35/02

Abstract: The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxy-cyclopentyl]methyl sulfamate (Compound I-263a) or a pharmaceutically acceptable salt, in combination with one or more anti-CD19 antibodies. Also provided are medicaments for use in treating cancer.

公开(公告)号：WO2023042096A1

公开(公告)日：2023-03-23

申请号：PCT/IB2022/058670

申请日：2022-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： HOEFINGHOFF, Joris ,  LEIDENMUEHLER, Peter ,  GANGADHARAN, Bagirath ,  HAIDER, Norbert ,  NAGY, Andras ,  LI, Zhaoyang

IPC: A61K38/47 ,  A61M5/44 ,  A61P37/00 ,  C07K16/06

Abstract: Provided is a concentrated pharmaceutical formulation of an immune globulin (IG), and convenient methods for the subcutaneous administration of this pharmaceutical formulation in a warmed state. Such products can be used in methods of treating IG-treatable diseases or conditions. Also provided are combinations, compositions and kits containing an immune globulin (IG) composition and a soluble hyaluronidase composition formulated for subcutaneous administration.

公开(公告)号：WO2023009700A2

公开(公告)日：2023-02-02

申请号：PCT/US2022/038640

申请日：2022-07-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  SHAPIRO, Gary

Inventor： TAKE, Chihiro ,  KASSAI, Yoshiaki ,  HE, Xingyue ,  KUHN, Chantal

IPC: C07K16/28 ,  C07K16/30 ,  C12N15/86 ,  A61K2039/5156 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/523 ,  C07K14/5443 ,  C07K14/7051 ,  C07K2317/622 ,  C07K2319/03

Abstract: Disclosed herein are engineered immune cells that specifically recognizes mesothelin and expresses IL-15 and optionally CCL19. Also disclosed herein are isolated nucleic acid molecules comprising a polynucleotide encoding a chimeric antigen receptor (CAR) comprising an antibody that specifically recognizes mesothelin, and a 4- IBB intracellular region; and a polynucleotide encoding IL- 15; and optionally a polynucleotide encoding CCL19, vectors, pharmaceutical compositions comprising the nucleic acid molecules, and methods of using the engineered immune cells.